<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Des Devel Ther</journal-id><journal-id journal-id-type="iso-abbrev">Drug Des Devel Ther</journal-id><journal-id journal-id-type="publisher-id">Drug Design, Development and Therapy</journal-id><journal-title-group><journal-title>Drug Design, Development and Therapy</journal-title></journal-title-group><issn pub-type="epub">1177-8881</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26508834</article-id><article-id pub-id-type="pmc">4610775</article-id><article-id pub-id-type="doi">10.2147/DDDT.S93150</article-id><article-id pub-id-type="publisher-id">dddt-9-5595</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Urinary kallidinogenase for the treatment of cerebral arterial stenosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Liandong</given-names></name><xref ref-type="aff" rid="af1-dddt-9-5595">1</xref><xref ref-type="aff" rid="af2-dddt-9-5595">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="af2-dddt-9-5595">2</xref></contrib><contrib contrib-type="author"><name><surname>Wan</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="af1-dddt-9-5595">1</xref><xref ref-type="corresp" rid="c1-dddt-9-5595"></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Haijun</given-names></name><xref ref-type="aff" rid="af3-dddt-9-5595">3</xref><xref ref-type="corresp" rid="c2-dddt-9-5595"></xref></contrib></contrib-group><aff id="af1-dddt-9-5595"><label>1</label>Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China</aff><aff id="af2-dddt-9-5595"><label>2</label>Department of Neurology, The Second People’s Hospital of Huai’an and The Affiliated Huai’an Hospital of Xuzhou Medical College, Huai’an, Jiangsu, People’s Republic of China</aff><aff id="af3-dddt-9-5595"><label>3</label>Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China</aff><author-notes><corresp id="c1-dddt-9-5595">Correspondence: Qi Wan, Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300, Nanjing 210029, People’s Republic of China, Tel +86 25 8371 4511, Fax +86 25 8626 0332, Email <email>wanqisry@sina.com</email></corresp><corresp id="c2-dddt-9-5595">Haijun Zhang, Department of Oncology, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao, Nanjing 210009, People’s Republic of China, Tel/fax +86 25 8327 5418, Email <email>zhanghaijunseu@163.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>13</day><month>10</month><year>2015</year></pub-date><volume>9</volume><fpage>5595</fpage><lpage>5600</lpage><permissions><copyright-statement>© 2015 Zhao et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2015</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title><offsets xml_i="4015" xml_f="4018" txt_i="11" txt_f="14">Aim</offsets></title><p><offsets xml_i="4029" xml_f="4267" txt_i="15" txt_f="253">Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis.</offsets></p></sec><sec><title><offsets xml_i="4289" xml_f="4296" txt_i="255" txt_f="262">Methods</offsets></title><p><offsets xml_i="4307" xml_f="4639" txt_i="263" txt_f="595">Ninety patients with cerebral arterial stenosis were enrolled, of whom 45 patients received UK + conventional treatment (UK group), and 45 patients received conventional treatment alone as control group. Cognitive status and Aβ1-40 and Aβ1-42 serum levels were determined before treatment and at 4 weeks and 8 weeks after treatment.</offsets></p></sec><sec><title><offsets xml_i="4661" xml_f="4668" txt_i="597" txt_f="604">Results</offsets></title><p><offsets xml_i="4679" xml_f="5042" txt_i="605" txt_f="968">At 4 weeks after treatment, cognitive status in patients treated with UK clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42. Cognitive status in patients receiving UK continued to improve, Aβ1-40 serum levels declined further as well as Aβ1-42 serum levels began to decrease dramatically at 8 weeks after treatment.</offsets></p></sec><sec><title><offsets xml_i="5064" xml_f="5074" txt_i="970" txt_f="980">Conclusion</offsets></title><p><offsets xml_i="5085" xml_f="5281" txt_i="981" txt_f="1177">UK could improve cognitive status and decrease both Aβ1-40 and Aβ1-42 serum levels to prevent ischemic cerebral injury, which represents a good option for patients with cerebral arterial stenosis.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>urinary kallidinogenase</kwd><kwd>arterial stenosis</kwd><kwd>Alzheimer’s disease</kwd><kwd>Aβ1-40</kwd><kwd>Aβ1-42</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="5532" xml_f="5544" txt_i="1186" txt_f="1198">Introduction</offsets></title><p><offsets xml_i="5555" xml_f="5718" txt_i="1199" txt_f="1362">Urinary kallikrein, a glycoprotein extracted from urine, can activate kallikrein–kinin system (KKS) and thus transfer kininogen hydrolysis into kallidin and kinin.</offsets><xref rid="b1-dddt-9-5595" ref-type="bibr"><offsets xml_i="5761" xml_f="5762" txt_i="1362" txt_f="1363">1</offsets></xref><offsets xml_i="5769" xml_f="5955" txt_i="1363" txt_f="1549"> Kinin in turn could activate B1 and B2 receptors induced by ischemic brain tissue and trigger a series of biological effects, releasing nitric oxide and relaxing vascular smooth muscle.</offsets><xref rid="b1-dddt-9-5595" ref-type="bibr"><offsets xml_i="5998" xml_f="5999" txt_i="1549" txt_f="1550">1</offsets></xref><offsets xml_i="6006" xml_f="6143" txt_i="1550" txt_f="1687"> Thus, it can expand blood vessels in the ischemic area, improve cerebral blood supply of penumbra, and restore the neurological deficit.</offsets><xref rid="b1-dddt-9-5595" ref-type="bibr"><offsets xml_i="6186" xml_f="6187" txt_i="1687" txt_f="1688">1</offsets></xref><offsets xml_i="6194" xml_f="6248" txt_i="1688" txt_f="1742"> Urinary kallidinogenase (UK) for injection (Kailikang</offsets><sup><offsets xml_i="6253" xml_f="6254" txt_i="1742" txt_f="1743">®</offsets></sup><offsets xml_i="6260" xml_f="6473" txt_i="1743" txt_f="1956">; Techpool Bio-Pharma Co, Ltd, Guangdong, People’s Republic of China) has been approved by Chinese State Food and Drug Administration and used clinically in People’s Republic of China to treat patients with stroke</offsets><xref rid="b2-dddt-9-5595" ref-type="bibr"><offsets xml_i="6516" xml_f="6517" txt_i="1956" txt_f="1957">2</offsets></xref><offsets xml_i="6524" xml_f="6571" txt_i="1957" txt_f="2004"> (molecular formula and structure are shown in </offsets><xref ref-type="fig" rid="f1-dddt-9-5595"><offsets xml_i="6613" xml_f="6621" txt_i="2004" txt_f="2012">Figure 1</offsets></xref><offsets xml_i="6628" xml_f="6790" txt_i="2012" txt_f="2174">). In addition, studies on hind limb ischemia, cardiac infarction, and renal ischemia confirmed that kallikrein attempts to maintain an adequate tissue perfusion.</offsets><xref rid="b3-dddt-9-5595" ref-type="bibr"><offsets xml_i="6833" xml_f="6834" txt_i="2174" txt_f="2175">3</offsets></xref><offsets xml_i="6841" xml_f="6938" txt_i="2175" txt_f="2272"> However, whether the commercially available KKS-regulating medicine, UK for injection (Kailikang</offsets><sup><offsets xml_i="6943" xml_f="6944" txt_i="2272" txt_f="2273">®</offsets></sup><offsets xml_i="6950" xml_f="7047" txt_i="2273" txt_f="2370">), is capable to improve the outcome of the cerebral arterial stenosis has not been reported yet.</offsets></p><p><offsets xml_i="7054" xml_f="7248" txt_i="2371" txt_f="2565">Cerebral arterial stenosis, including intracranial and/or extracranial artery stenosis, is characterized by narrowed arteries that supply blood to the brain, resulting in cerebral hypoperfusion.</offsets><xref rid="b4-dddt-9-5595" ref-type="bibr"><offsets xml_i="7291" xml_f="7292" txt_i="2565" txt_f="2566">4</offsets></xref><offsets xml_i="7299" xml_f="7439" txt_i="2566" txt_f="2706"> Patients with severe cerebral artery stenosis run a higher risk of distal embolization, hemodynamic changes, and sudden vascular occlusion.</offsets><xref rid="b5-dddt-9-5595" ref-type="bibr"><offsets xml_i="7482" xml_f="7483" txt_i="2706" txt_f="2707">5</offsets></xref><offsets xml_i="7490" xml_f="7491" txt_i="2707" txt_f="2708">–</offsets><xref rid="b7-dddt-9-5595" ref-type="bibr"><offsets xml_i="7534" xml_f="7535" txt_i="2708" txt_f="2709">7</offsets></xref><offsets xml_i="7542" xml_f="7814" txt_i="2709" txt_f="2981"> Alzheimer’s disease (AD) is associated with decreased cerebral blood flow. It was found that AD cases displayed a degree of cerebral artery occlusion and that there was a positive correlation between the degree of arterial stenosis and neurofibrillary tangle (NFT) score.</offsets><xref rid="b8-dddt-9-5595" ref-type="bibr"><offsets xml_i="7857" xml_f="7858" txt_i="2981" txt_f="2982">8</offsets></xref><offsets xml_i="7865" xml_f="7990" txt_i="2982" txt_f="3107"> Chronic brain hypoperfusion leading to cerebral hypoxia represents an important aspect of neurodegenerative processes in AD.</offsets><xref rid="b9-dddt-9-5595" ref-type="bibr"><offsets xml_i="8033" xml_f="8034" txt_i="3107" txt_f="3108">9</offsets></xref><offsets xml_i="8041" xml_f="8323" txt_i="3108" txt_f="3390"> The current hypothesis of the pathogenesis of familial AD results mainly from aberrant cleavage of amyloid beta (Aβ) precursor protein, which produces cytotoxic Aβ fragments, causes progressive degeneration and dysfunction of neurons, and ultimately leads to the development of AD.</offsets><xref rid="b4-dddt-9-5595" ref-type="bibr"><offsets xml_i="8366" xml_f="8367" txt_i="3390" txt_f="3391">4</offsets></xref><offsets xml_i="8374" xml_f="8520" txt_i="3391" txt_f="3537"> The contribution of Aβ deposition in the pathogenesis of AD has been well established, and Aβ appears to have a role in ischemic cerebral damage.</offsets><xref rid="b10-dddt-9-5595" ref-type="bibr"><offsets xml_i="8564" xml_f="8566" txt_i="3537" txt_f="3539">10</offsets></xref></p><p><offsets xml_i="8580" xml_f="9107" txt_i="3540" txt_f="4067">For patients with cerebral arterial stenosis, improving the cerebrovascular perfusion remains a good option to rescue injured tissue and alleviate neurological deficits. In this study, we evaluated the cognitive status and the serum levels of Aβ1-40 and Aβ1-42 in patients with cerebral arterial stenosis treated with or without UK before treatment and at 4 weeks and 8 weeks after treatment. Our intention was to provide additional evidence on the efficacy of UK in the application of patients with cerebral arterial stenosis.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="9158" xml_f="9179" txt_i="4069" txt_f="4090">Materials and methods</offsets></title><sec sec-type="subjects"><title><offsets xml_i="9219" xml_f="9227" txt_i="4091" txt_f="4099">Patients</offsets></title><p><offsets xml_i="9238" xml_f="9766" txt_i="4100" txt_f="4628">Ninety patients were recruited from the Second People’s Hospital of Huai’an from June 1, 2013, to May 31, 2015. The study was approved by the Ethics Committee of the Second People’s Hospital of Huai’an, and informed consents were obtained from all the participants. Patients with dizziness, transient ischemic attack, and 70% or more internal carotid artery stenosis on one or both sides as determined by neuroimaging examination such as digital subtraction angiography and magnetic resonance imaging were included in the study.</offsets><xref rid="b4-dddt-9-5595" ref-type="bibr"><offsets xml_i="9809" xml_f="9810" txt_i="4628" txt_f="4629">4</offsets></xref><offsets xml_i="9817" xml_f="10028" txt_i="4629" txt_f="4840"> Patients were excluded if they had a history of major medical illness, such as heart failure, pulmonary insufficiency, renal insufficiency, hepatic dysfunction, or blood diseases unfit for antiplatelet therapy.</offsets><xref rid="b4-dddt-9-5595" ref-type="bibr"><offsets xml_i="10071" xml_f="10072" txt_i="4840" txt_f="4841">4</offsets></xref><offsets xml_i="10079" xml_f="11427" txt_i="4841" txt_f="6189"> Participants were randomly assigned (1:1) to receive either a UK treatment (UK group) or a conventional treatment (control group) using a computer-generated random sequence. The UK group consisted of 45 patients (24 men and 21 women) aged from 42 years to 84 years, including 21 cases of unilateral internal carotid artery stenosis, twelve cases of bilateral internal carotid artery stenosis, eight cases of unilateral internal carotid artery stenosis associated with vertebral artery stenosis, and four cases of unilateral internal carotid artery stenosis associated with middle cerebral artery stenosis. The control group also consisted of 45 patients (26 men and 19 women) aged from 40 years to 79 years, including 19 cases of unilateral internal carotid artery stenosis, eleven cases of bilateral internal carotid artery stenosis, ten cases of unilateral internal carotid artery stenosis associated with vertebral artery stenosis, and five cases of unilateral internal carotid artery stenosis associated with middle cerebral artery stenosis. All patients had experienced at least 1 month of nervous-system dysfunctions. No severe cerebrovascular problems such as stroke occurred during the study period. Clinical symptoms of cerebral ischemia, such as paralysis of limbs and/or disturbance of consciousness, were observed in most of the cases.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="11468" xml_f="11478" txt_i="6191" txt_f="6201">Procedures</offsets></title><p><offsets xml_i="11489" xml_f="11521" txt_i="6202" txt_f="6234">The study procedure is shown in </offsets><xref ref-type="fig" rid="f2-dddt-9-5595"><offsets xml_i="11563" xml_f="11571" txt_i="6234" txt_f="6242">Figure 2</offsets></xref><offsets xml_i="11578" xml_f="13108" txt_i="6242" txt_f="7772">. During the study period, all patients were given 75 mg of clopidogrel and 100 mg of enteric-coated aspirin orally once a day in addition to the use of salvia, puerarin (Conba Phamaceuticals, Zhejiang, People’s Republic of China), and an anti-free-radical agent, edaravone (Lijun Phamaceuticals, Xian, People’s Republic of China), as conventional treatment in the control group. In addition, UK was injected into patients in the UK group at a dose of 0.15 paranitroanilinum (PNA)/d every day for 21 days. There was no daily and total effect of a daily injection of UK on blood pressure (BP), pulse rate, and heart rate. Mini-mental state examination (MMSE) scale was performed to evaluate the efficacy of UK on the cognitive status before treatment and at 4 weeks and 8 weeks after treatment in all patients. MMSE scale was scored by experienced neurologists, who had over 10 years of experience in professional neuropsychological scale assessment and were blinded to the clinical findings. Moreover, 5 mL blood samples were collected via cubital vein from patients before treatment and at 4 weeks and 8 weeks after treatment. The blood samples were centrifuged at 1,000 rpm for 10 minutes, and sera were immediately collected and stored at −70°C. Then, serum concentrations of Aβ were determined using solid-phase sandwich enzyme-linked immunosorbent assay kit as per the manufacturer’s instructions (Adlitteram Diagnostic Laboratories, San Diego, CA, USA). Furthermore, the evaluator of Aβ was blind to the results of grouping.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="13149" xml_f="13169" txt_i="7774" txt_f="7794">Statistical analysis</offsets></title><p><offsets xml_i="13180" xml_f="13416" txt_i="7795" txt_f="8031">Statistical analyses were performed using SPSS software (Version 10.0; IBM Corporation, Armonk, NY, USA). Continuous variables were expressed as mean ± standard deviation, whereas categorical variables were expressed as percentage. The </offsets><italic><offsets xml_i="13424" xml_f="13425" txt_i="8031" txt_f="8032">F</offsets></italic><offsets xml_i="13434" xml_f="13507" txt_i="8032" txt_f="8105">-test was used for significance testing of continuous variables, and the </offsets><italic><offsets xml_i="13515" xml_f="13516" txt_i="8105" txt_f="8106">χ</offsets></italic><sup><offsets xml_i="13530" xml_f="13531" txt_i="8106" txt_f="8107">2</offsets></sup><offsets xml_i="13537" xml_f="13595" txt_i="8107" txt_f="8165"> statistic was used for testing of categorical variables. </offsets><italic><offsets xml_i="13603" xml_f="13604" txt_i="8165" txt_f="8166">P</offsets></italic><offsets xml_i="13613" xml_f="13669" txt_i="8166" txt_f="8219">&lt;0.05 was considered to be statistically significant.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="13716" xml_f="13723" txt_i="8222" txt_f="8229">Results</offsets></title><sec sec-type="intro|subjects"><title><offsets xml_i="13769" xml_f="13805" txt_i="8230" txt_f="8266">Characteristics of enrolled patients</offsets></title><p><offsets xml_i="13816" xml_f="13828" txt_i="8267" txt_f="8279">As shown in </offsets><xref ref-type="table" rid="t1-dddt-9-5595"><offsets xml_i="13872" xml_f="13879" txt_i="8279" txt_f="8286">Table 1</offsets></xref><offsets xml_i="13886" xml_f="14131" txt_i="8286" txt_f="8531">, 90 patients were enrolled, of whom 45 patients received conventional treatment + UK (UK group) and another 45 patients only received conventional treatment (control group), and the two groups were similar in basic characteristics for analysis.</offsets></p></sec><sec><title><offsets xml_i="14153" xml_f="14198" txt_i="8533" txt_f="8578">Comparison of MMSE before and after treatment</offsets></title><p><offsets xml_i="14209" xml_f="14400" txt_i="8579" txt_f="8770">To investigate the effect of UK on the cognitive status in patients with cerebral arterial stenosis, we first evaluated the cognitive status with MMSE scale before any treatment. As shown in </offsets><xref ref-type="fig" rid="f3-dddt-9-5595"><offsets xml_i="14442" xml_f="14450" txt_i="8770" txt_f="8778">Figure 3</offsets></xref><offsets xml_i="14457" xml_f="14811" txt_i="8778" txt_f="9132">, there was no obvious difference of the score of MMSE between the UK group and the control group before any treatment. The score of MMSE obviously improved at 4 weeks and 8 weeks after patients treated with UK. However, during the study, the MMSE score of patients with conventional treatment still remained similar to that of patients before treatment.</offsets></p></sec><sec><title><offsets xml_i="14833" xml_f="14867" txt_i="9134" txt_f="9168">Effect of UK on serum levels of Aβ</offsets></title><p><offsets xml_i="14878" xml_f="14890" txt_i="9169" txt_f="9181">As shown in </offsets><xref ref-type="table" rid="t2-dddt-9-5595"><offsets xml_i="14934" xml_f="14941" txt_i="9181" txt_f="9188">Table 2</offsets></xref><offsets xml_i="14948" xml_f="15484" txt_i="9188" txt_f="9724">, no significant difference was found in the serum levels of Aβ1-40 and Aβ1-42 between the UK group and the control group before treatment. There were no significant changes of both Aβ1-40 and Aβ1-42 in the control group throughout the study. However, the serum levels of Aβ1-40 in the UK group decreased significantly at 4 weeks after treatment and further 8 weeks after treatment. The serum levels of Aβ1-42 in the UK group display different manners than that of Aβ1-40 that began to decrease significantly at 8 weeks after treatment.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="15534" xml_f="15544" txt_i="9727" txt_f="9737">Discussion</offsets></title><p><offsets xml_i="15555" xml_f="15794" txt_i="9738" txt_f="9977">Perfusion and hypoxia due to cerebral arterial stenosis may promote β-site cleavage of Aβ precursor protein and cleavage activity of γ-secretase, resulting in increased levels of various Aβ fragments such as Aβ1-40 and Aβ1-42 in the brain.</offsets><xref rid="b4-dddt-9-5595" ref-type="bibr"><offsets xml_i="15837" xml_f="15838" txt_i="9977" txt_f="9978">4</offsets></xref><offsets xml_i="15845" xml_f="16012" txt_i="9978" txt_f="10145"> An imbalance between production and clearance of Aβ fragments may cause abnormal accumulation of these peptides inside the brain and the subsequent development of AD.</offsets><xref rid="b11-dddt-9-5595" ref-type="bibr"><offsets xml_i="16056" xml_f="16058" txt_i="10145" txt_f="10147">11</offsets></xref><offsets xml_i="16065" xml_f="16066" txt_i="10147" txt_f="10148">–</offsets><xref rid="b13-dddt-9-5595" ref-type="bibr"><offsets xml_i="16110" xml_f="16112" txt_i="10148" txt_f="10150">13</offsets></xref><offsets xml_i="16119" xml_f="16384" txt_i="10150" txt_f="10415"> Various mechanisms are involved in the detrimental effects of Aβ. For example, Aβ could activate astrocytes and microglias and cause inflammatory reactions via stimulating expression and release of tumor necrosis factor-alpha, interleukin-1, interleukin-6, and NO.</offsets><xref rid="b14-dddt-9-5595" ref-type="bibr"><offsets xml_i="16428" xml_f="16430" txt_i="10415" txt_f="10417">14</offsets></xref><offsets xml_i="16437" xml_f="16438" txt_i="10417" txt_f="10418">,</offsets><xref rid="b15-dddt-9-5595" ref-type="bibr"><offsets xml_i="16482" xml_f="16484" txt_i="10418" txt_f="10420">15</offsets></xref><offsets xml_i="16491" xml_f="16636" txt_i="10420" txt_f="10565"> Aβ might also induce nerve-cell apoptosis and disrupt the automatic regulation of vasomotion, collectively aggravating ischemic cerebral damage.</offsets><xref rid="b4-dddt-9-5595" ref-type="bibr"><offsets xml_i="16679" xml_f="16680" txt_i="10565" txt_f="10566">4</offsets></xref><offsets xml_i="16687" xml_f="16977" txt_i="10566" txt_f="10856"> Meanwhile, vascular risk factors can predict the clinical development of cognitive dysfunction. Cerebral hypoperfusion can lead to major reductions in suboptimal delivery of high-energy nutrients to the brain, with lethal consequences to brain cells that participate in cognitive function.</offsets><xref rid="b16-dddt-9-5595" ref-type="bibr"><offsets xml_i="17021" xml_f="17023" txt_i="10856" txt_f="10858">16</offsets></xref><offsets xml_i="17030" xml_f="17031" txt_i="10858" txt_f="10859">–</offsets><xref rid="b20-dddt-9-5595" ref-type="bibr"><offsets xml_i="17075" xml_f="17077" txt_i="10859" txt_f="10861">20</offsets></xref><offsets xml_i="17084" xml_f="17256" txt_i="10861" txt_f="11033"> Thus, expanding the blood vessels, improving the cerebral blood supply, and restoring the neurological deficit are urgent for the patients with cerebral arterial stenosis.</offsets></p><p><offsets xml_i="17263" xml_f="17585" txt_i="11034" txt_f="11356">UK is a positive regulatory substance in KKS consisting of kinins, kallikreins, and kininogens by producing kallidin and kinin, and has been identified to protect against ischemic brain injury through multiple signaling pathways, including anti-inflammation and antiapoptosis, and to promote angiogenesis and neurogenesis.</offsets><xref rid="b21-dddt-9-5595" ref-type="bibr"><offsets xml_i="17629" xml_f="17631" txt_i="11356" txt_f="11358">21</offsets></xref><offsets xml_i="17638" xml_f="17639" txt_i="11358" txt_f="11359">,</offsets><xref rid="b22-dddt-9-5595" ref-type="bibr"><offsets xml_i="17683" xml_f="17685" txt_i="11359" txt_f="11361">22</offsets></xref><offsets xml_i="17692" xml_f="17936" txt_i="11361" txt_f="11605"> UK could supply kallikrein to patients’ salvages brain tissue by expanding blood vessels, recanalizing, and improving perfusion. The study on the efficacy of UK in stroke demonstrated that patients could benefit from it with 87% efficacy rate.</offsets><xref rid="b2-dddt-9-5595" ref-type="bibr"><offsets xml_i="17979" xml_f="17980" txt_i="11605" txt_f="11606">2</offsets></xref><offsets xml_i="17987" xml_f="18593" txt_i="11606" txt_f="12212"> In this study, we studied 45 patients with cerebral arterial stenosis that received UK could improve the cognitive status at 4 weeks after treatment than conventional treatment. Meanwhile, improved cognitive status in patients accompanied by Aβ1-40 decrease at 4 weeks after treatment and by Aβ1-42 decrease at 8 weeks after treatment, possibly through decreased production or increased clearance of Aβ fragments in cerebral tissues due to improved cerebral blood flow by UK. The findings in this study are consistent with most of the previous studies about UK for ischemic cerebral injury such as stroke.</offsets><xref rid="b2-dddt-9-5595" ref-type="bibr"><offsets xml_i="18636" xml_f="18637" txt_i="12212" txt_f="12213">2</offsets></xref><offsets xml_i="18644" xml_f="18909" txt_i="12213" txt_f="12478"> Furthermore, in this study, there is no side effect of hypotension, the most common adverse event of UK, on the patients using the new treatment method, which provides the evidence on the safety of UK in the application of patients with cerebral arterial stenosis.</offsets></p><p><offsets xml_i="18916" xml_f="19272" txt_i="12479" txt_f="12835">Taken together, this study at first confirmed that UK could improve cognitive status and decrease Aβs to prevent the development and progression of AD and ischemic cerebral injury, which could represent an approach for patients with cerebral arterial stenosis. Due to the limitation of the short follow-up period, further investigation is needed in future.</offsets></p></sec><sec><title><offsets xml_i="19294" xml_f="19304" txt_i="12837" txt_f="12847">Conclusion</offsets></title><p><offsets xml_i="19315" xml_f="19632" txt_i="12848" txt_f="13165">In conclusion, UK successfully improved cognitive status in patients with cerebral arterial stenosis and decreased both Aβ1-40 and Aβ1-42 serum levels. Therapeutic strategy of the supplement of kallikreins to increase cerebral blood flow may prevent the development and progression of AD and ischemic cerebral injury.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Xinyong Zhang, Zengjun Wang, Jingming Lu, and Guang Yang for assistance with patient recruitment.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-dddt-9-5595"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YX</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>CH</given-names></name><etal></etal></person-group><article-title>Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2015</year><volume>19</volume><issue>6</issue><fpage>1009</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">25855926</pub-id></element-citation></ref><ref id="b2-dddt-9-5595"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Tao</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group><article-title>Efficacy and safety of human urinary kallidinogenase injection for acute ischemic stroke: a systematic review</article-title><source>J Evid Based Med</source><year>2012</year><volume>5</volume><issue>1</issue><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">23528118</pub-id></element-citation></ref><ref id="b3-dddt-9-5595"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porcu</surname><given-names>P</given-names></name><name><surname>Emanueli</surname><given-names>C</given-names></name><name><surname>Kapatsoris</surname><given-names>M</given-names></name><name><surname>Chao</surname><given-names>J</given-names></name><name><surname>Chao</surname><given-names>L</given-names></name><name><surname>Madeddu</surname><given-names>P</given-names></name></person-group><article-title>Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia</article-title><source>Circulation</source><year>2002</year><volume>105</volume><issue>1</issue><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">11772878</pub-id></element-citation></ref><ref id="b4-dddt-9-5595"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Effect of stent-assisted angioplasty on cognitive status and serum levels of amyloid beta in patients with intracranial and/or extracranial artery stenosis</article-title><source>Neuropsychiatr Dis Treat</source><year>2015</year><volume>11</volume><fpage>471</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">25750527</pub-id></element-citation></ref><ref id="b5-dddt-9-5595"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>PQ</given-names></name><name><surname>Wang</surname><given-names>AP</given-names></name><name><surname>Cao</surname><given-names>ZH</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>GB</given-names></name></person-group><article-title>The study of the distribution character of cerebral arterial stenosis in patients with ischemic cerebrovascular disease by means of 64 slices CT</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2015</year><volume>19</volume><issue>12</issue><fpage>2287</fpage><lpage>2292</lpage><pub-id pub-id-type="pmid">26166656</pub-id></element-citation></ref><ref id="b6-dddt-9-5595"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Chung</surname><given-names>CY</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Tang</surname><given-names>SF</given-names></name><name><surname>Pei</surname><given-names>YC</given-names></name></person-group><article-title>Increased risk of posterior circulation infarcts among ischemic stroke patients with cervical spondylosis</article-title><source>Neuropsychiatr Dis Treat</source><year>2015</year><volume>11</volume><fpage>273</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">25678792</pub-id></element-citation></ref><ref id="b7-dddt-9-5595"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolukısa</surname><given-names>M</given-names></name><name><surname>Ozdemir Gültekin</surname><given-names>T</given-names></name><name><surname>Eryigit Baran</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>One-year follow-up in patients with brainstem infarction due to large-artery atherothrombosis</article-title><source>Neuropsychiatr Dis Treat</source><year>2015</year><volume>11</volume><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">25733838</pub-id></element-citation></ref><ref id="b8-dddt-9-5595"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roher</surname><given-names>AE</given-names></name><name><surname>Esh</surname><given-names>C</given-names></name><name><surname>Kokjohn</surname><given-names>TA</given-names></name><etal></etal></person-group><article-title>Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer’s disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2003</year><volume>23</volume><issue>11</issue><fpage>2055</fpage><lpage>2062</lpage><pub-id pub-id-type="pmid">14512367</pub-id></element-citation></ref><ref id="b9-dddt-9-5595"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinzel</surname><given-names>S</given-names></name><name><surname>Liepelt-Scarfone</surname><given-names>I</given-names></name><name><surname>Roeben</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>A neurodegenerative vascular burden index and the impact on cognition</article-title><source>Front Aging Neurosci</source><year>2014</year><volume>6</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">25071568</pub-id></element-citation></ref><ref id="b10-dddt-9-5595"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal></etal></person-group><article-title>Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer’s disease neuropathology in APPSwe/PS1A246E transgenic mice</article-title><source>Neurobiol Aging</source><year>2013</year><volume>34</volume><issue>3</issue><fpage>663</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">22795785</pub-id></element-citation></ref><ref id="b11-dddt-9-5595"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Qazzaz</surname><given-names>NK</given-names></name><name><surname>Ali</surname><given-names>SH</given-names></name><name><surname>Ahmad</surname><given-names>SA</given-names></name><name><surname>Islam</surname><given-names>S</given-names></name><name><surname>Mohamad</surname><given-names>K</given-names></name></person-group><article-title>Cognitive impairment and memory dysfunction after a stroke diagnosis: a post-stroke memory assessment</article-title><source>Neuropsychiatr Dis Treat</source><year>2014</year><volume>10</volume><fpage>1677</fpage><lpage>1691</lpage><pub-id pub-id-type="pmid">25228808</pub-id></element-citation></ref><ref id="b12-dddt-9-5595"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>L</given-names></name><name><surname>Scarpini</surname><given-names>E</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name></person-group><article-title>Disease-modifying drugs in Alzheimer’s disease</article-title><source>Drug Des Devel Ther</source><year>2013</year><volume>7</volume><fpage>1471</fpage><lpage>1478</lpage></element-citation></ref><ref id="b13-dddt-9-5595"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LF</given-names></name><name><surname>Zhou</surname><given-names>ZW</given-names></name><name><surname>Wang</surname><given-names>ZH</given-names></name><etal></etal></person-group><article-title>Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells</article-title><source>Drug Des Devel Ther</source><year>2014</year><volume>9</volume><fpage>241</fpage><lpage>272</lpage></element-citation></ref><ref id="b14-dddt-9-5595"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name></person-group><article-title>Neuroinflammation in Alzheimer’s disease</article-title><source>Neuropsychiatr Dis Treat</source><year>2015</year><volume>11</volume><fpage>243</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">25673992</pub-id></element-citation></ref><ref id="b15-dddt-9-5595"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuttolomondo</surname><given-names>A</given-names></name><name><surname>Pecoraro</surname><given-names>R</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name></person-group><article-title>Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date</article-title><source>Drug Des Devel Ther</source><year>2014</year><volume>8</volume><fpage>2221</fpage><lpage>2239</lpage></element-citation></ref><ref id="b16-dddt-9-5595"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Torre</surname><given-names>JC</given-names></name></person-group><article-title>Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer’s disease</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>32</volume><fpage>553</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">22842871</pub-id></element-citation></ref><ref id="b17-dddt-9-5595"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestrini</surname><given-names>M</given-names></name><name><surname>Viticchi</surname><given-names>G</given-names></name><name><surname>Falsetti</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>The role of carotid atherosclerosis in Alzheimer’s disease progression</article-title><source>J Alzheimers Dis</source><year>2011</year><volume>25</volume><fpage>719</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">21508532</pub-id></element-citation></ref><ref id="b18-dddt-9-5595"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestrini</surname><given-names>M</given-names></name><name><surname>Viticchi</surname><given-names>G</given-names></name><name><surname>Altamura</surname><given-names>C</given-names></name><name><surname>Luzzi</surname><given-names>S</given-names></name><name><surname>Balucani</surname><given-names>C</given-names></name><name><surname>Vernieri</surname><given-names>F</given-names></name></person-group><article-title>Cerebrovascular assessment for the risk prediction of Alzheimer’s disease</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>32</volume><fpage>689</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">22886022</pub-id></element-citation></ref><ref id="b19-dddt-9-5595"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balestrini</surname><given-names>S</given-names></name><name><surname>Perozzi</surname><given-names>C</given-names></name><name><surname>Altamura</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Severe carotid stenosis and impaired cerebral hemodynamics can influence cognitive deterioration</article-title><source>Neurology</source><year>2013</year><volume>80</volume><fpage>2145</fpage><lpage>2150</lpage><pub-id pub-id-type="pmid">23624562</pub-id></element-citation></ref><ref id="b20-dddt-9-5595"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name></person-group><article-title>Impaired Aβ clearance: a potential link between atherosclerosis and Alzheimer’s disease</article-title><source>Front Aging Neurosci</source><year>2015</year><volume>7</volume><fpage>115</fpage><pub-id pub-id-type="pmid">26136682</pub-id></element-citation></ref><ref id="b21-dddt-9-5595"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>ZB</given-names></name><name><surname>Huang</surname><given-names>DQ</given-names></name><name><surname>Niu</surname><given-names>FN</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>EG</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB</article-title><source>J Cereb Blood Flow Metab</source><year>2010</year><volume>30</volume><fpage>1356</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">20179726</pub-id></element-citation></ref><ref id="b22-dddt-9-5595"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert-Weißenberger</surname><given-names>C</given-names></name><name><surname>Sirén</surname><given-names>AL</given-names></name><name><surname>Kleinschnitz</surname><given-names>C</given-names></name></person-group><article-title>Ischemic stroke and traumatic brain injury: the role of the kallikrein-kinin system</article-title><source>Prog Neurobiol</source><year>2013</year><volume>10</volume><issue>1–102</issue><fpage>65</fpage><lpage>82</lpage></element-citation></ref></ref-list></back><floats-group><fig id="f1-dddt-9-5595" position="float"><label>Figure 1</label><caption><p>Molecular formula (<bold>A</bold>) and structure (<bold>B</bold>) of urinary kallidinogenase.</p></caption><graphic xlink:href="dddt-9-5595Fig1"></graphic></fig><fig id="f2-dddt-9-5595" position="float"><label>Figure 2</label><caption><p>The schedule of the study.</p><p><bold>Abbreviations:</bold> MMSE, mini-mental state examination; UK, urinary kallidinogenase.</p></caption><graphic xlink:href="dddt-9-5595Fig2"></graphic></fig><fig id="f3-dddt-9-5595" position="float"><label>Figure 3</label><caption><p>MMSE scores before and after treatment.</p><p><bold>Note:</bold>
<sup>*</sup><italic>P</italic>&lt;0.05.</p><p><bold>Abbreviations:</bold> MMSE, mini-mental state examination; UK, urinary kallidinogenase.</p></caption><graphic xlink:href="dddt-9-5595Fig3"></graphic></fig><table-wrap id="t1-dddt-9-5595" position="float"><label>Table 1</label><caption><p>Characteristics of enrolled patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">UK group</th><th valign="top" align="left" rowspan="1" colspan="1">Control group</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years), (mean ± SD)</td><td valign="top" align="left" rowspan="1" colspan="1">57.26±9.35</td><td valign="top" align="left" rowspan="1" colspan="1">56.81±9.27</td><td valign="top" align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0.67</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Distribution of arterial stenosis</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Unilateral ICA</td><td valign="top" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Bilateral ICA</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Unilateral ICA + VA</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Unilateral ICA + MCA</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-dddt-9-5595"><p><bold>Abbreviations:</bold> UK, urinary kallidinogenase; ICA, internal carotid artery; VA, vertebral artery; MCA, middle cerebral artery.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-dddt-9-5595" position="float"><label>Table 2</label><caption><p>Effect of UK on serum levels of amyloid beta</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Aβ</th><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1">Before treatment (ng/L)</th><th valign="top" align="left" rowspan="1" colspan="1">4 weeks after treatment (ng/L)</th><th valign="top" align="left" rowspan="1" colspan="1">8 weeks after treatment (ng/L)</th></tr></thead><tbody><tr><td rowspan="2" valign="top" align="left" colspan="1">Aβ1-40</td><td valign="top" align="left" rowspan="1" colspan="1">UK</td><td valign="top" align="left" rowspan="1" colspan="1">1.25±0.29</td><td valign="top" align="left" rowspan="1" colspan="1">1.01±0.22<xref ref-type="table-fn" rid="tfn3-dddt-9-5595">*</xref>,<xref ref-type="table-fn" rid="tfn4-dddt-9-5595">**</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.87±0.18<xref ref-type="table-fn" rid="tfn3-dddt-9-5595">*</xref>,<xref ref-type="table-fn" rid="tfn4-dddt-9-5595">**</xref>,<xref ref-type="table-fn" rid="tfn5-dddt-9-5595">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">1.24±0.33</td><td valign="top" align="left" rowspan="1" colspan="1">1.14±0.27</td><td valign="top" align="left" rowspan="1" colspan="1">1.16±0.24</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Aβ1-42</td><td valign="top" align="left" rowspan="1" colspan="1">UK</td><td valign="top" align="left" rowspan="1" colspan="1">0.95±0.21</td><td valign="top" align="left" rowspan="1" colspan="1">0.94±0.23</td><td valign="top" align="left" rowspan="1" colspan="1">0.75±0.18<xref ref-type="table-fn" rid="tfn3-dddt-9-5595">*</xref>,<xref ref-type="table-fn" rid="tfn4-dddt-9-5595">**</xref>,<xref ref-type="table-fn" rid="tfn5-dddt-9-5595">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">0.93±0.33</td><td valign="top" align="left" rowspan="1" colspan="1">0.94±0.28</td><td valign="top" align="left" rowspan="1" colspan="1">0.93±0.32</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-dddt-9-5595"><p><bold>Notes:</bold> Data are presented as mean ± SD. Compared with control group,</p></fn><fn id="tfn3-dddt-9-5595"><label>*</label><p><italic>P</italic>&lt;0.05; compared with before treatment,</p></fn><fn id="tfn4-dddt-9-5595"><label>**</label><p><italic>P</italic>&lt;0.05; compared with 4 weeks after treatment,</p></fn><fn id="tfn5-dddt-9-5595"><label>***</label><p><italic>P</italic>&lt;0.05.</p></fn><fn id="tfn6-dddt-9-5595"><p><bold>Abbreviation:</bold> UK, urinary kallidinogenase.</p></fn></table-wrap-foot></table-wrap></floats-group></article>